Drug Profile


Alternative Names: KRP-114V; MK-4618

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Kyorin Pharmaceutical; Merck & Co
  • Class Antihypertensives; Antispasmodics; Pyrimidines; Pyrrolidines; Small molecules; Tetrapyrroles
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Overactive bladder
  • Discontinued Endocrine disorders; Hypertension

Most Recent Events

  • 06 Nov 2017 Kyorin Pharmaceutical completes a phase III trial in Overactive bladder in Japan (PO, once-daily) (JapicCTI-152800)
  • 18 Sep 2017 Urovant Sciences plans a phase III programme for Overactive bladder in early 2018
  • 06 Jun 2017 Vibegron licensed to Urovant Sciences worldwide for the treatment of Overactive bladder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top